Correction: In vitro drug testing using patient-derived ovarian cancer organoids

Chen, Lin-Yu; Chou, Yu-Ting; Liew, Phui-Ly; Chu, Ling-Hui; Wen, Kuo-Chang; Lin, Shiou-Fu; Weng, Yu-Chun; Wang, Hui-Chen; Su, Po-Hsuan; Lai, Hung-Cheng

doi:10.1186/s13048-024-01559-1

Journal of Ovarian Research

Table 1 The characteristics of patients with ovarian cancer

From: Correction: In vitro drug testing using patient-derived ovarian cancer organoids

Original ID	Sample ID	Cancer type	Age	FIGO stage	Neoadjuvant chemotherapy	Debulking status	Adjuvant chemotherapy	Survival status	BRCA geme status	Organoid culture	Organoid expansion
OvCa-19	HGSC-1	High grade serous	54	IIIC	Not received	Suboptimal	Paclitaxel and carboplatin x 6 cycles, followed by lipodox x12 cycles, then second debulking then paclitaxel and carboplatin x6 cycles	Alive	Wild type	Success	No
OvCa-21	EM-1	Endometrioid	40	IC1	Not received	Optimal	Paclitaxel and carboplatin x 9 cycles	Alive	Unexamined	Failed	-
OvCa-26	MC-1	Mucinous	37	IVB	Not received	Optimal	Paclitaxel and carboplatin x 6 cycles, followed by lipodox x 3 cycles, then gemcitabine and carboplatin x3 cycles	Expired	Unexamined	Success	Yes
OvCa-28	MC-2	Mucinous	66	IIIA	Not received	Optimal	Not received due to acute stroke	Expired	Unexamined	Success	Yes
OvCa-29	HGSC-2	High grade serous	61	IVB	Not received	Suboptimal	Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles	Alive	Wild type	Success	Yes
OvCa-32	HGSC-3	High grade serous	62	IVB	Not received	Suboptimal	Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles	Alive	Wild type	Failed	-
OvCa-33	HGSC-4	High grade serous	41	IIIC	Not received	Suboptimal	Paclitaxel and carboplatin x 6 cycles, then lipodox x 6 cycles	Alive	Mutation	Success	Yes
OvCa-34	MC-3	Mucinous	43	IC1	Not received	Optimal	Paclitaxel and cisplatin x4 cycles, then lipodox and bevacizumab x 5 cycles, then gemcitabine and bevacizumab x 2 cycles, then topotecan x 8 cycles	Expired	Unexamined	Failed	-
OvCa-37	CCSC-1	Carcinosarcoma	61	IIIC	Not received	Optimal	Paclitaxel, carboplatin and bevacizumab x 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine x2 cycles	Expired	Wild type	Success	Yes
OvCa-38	CCC-1	Clear cell	32	IC1	Not received	Optimal	Paclitaxel and carboplatin x 4 cycles	Alive	Unexamined	Success	Yes
OvCa-40	CCC-2	Clear cell	49	IIIC	Bevacizumab, paclitaxel and cisplatin x 3 cycle then paclitaxel and carboplatin x 2 cycle	Suboptimal	Gemcitabine and carboplatin x1 cycle	Expired	Unexamined	Success	Yes
OvCa-41	CCC-3	Clear cell	50	IIIB	Not received	Optimal	Rejected	Expired	Unexamined	Success	Yes
OvCa-42	MC-4	Mucinous	47	IC1	Not received	Optimal	Not received	Alive	Unexamined	Success	Yes
OvCa-43	HGSC-5	High grade serous	55	IIIC	Paclitaxel and carboplatin x 4 cycle	Optimal	Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycle	Expired	Wild type	Success	Yes
OvCa-44	EM-2	Endometrioid	58	IIB	Not received	Suboptimal	Paclitaxel and cisplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine and cisplatin x2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin x2 cycles	Alive	Unexamined	Success	Yes
OvCa-45	HGSC-6	High grade serous	70	IIIC	Not received	Optimal	Paclitaxel and carboplatin x 6 cycles, then lipodox and carboplatin x4 cycles	Alive	Unexamined	Success	No
OvCa-46	MC-5	Mucinous	44	IC1	Not received	Optimal	Not received	Alive	Unexamined	Success	Yes
OvCa-49	HGSC-7	High grade serous	55	IIIC	Paclitaxel and cisplatin x 4 cycle	Optimal	Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycles	Expired	Wild type	Success	Yes
OvCa-50	CCC-4	Clear cell	45	IIIC	Not received	Optimal	Paclitaxel and carboplatin x 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab x 1 cycle, then gemcitabine, carboplatin and bevacizumab x 8 cycles.	Alive	Unexamined	Success	Yes
OvCa-51	CCSC-2	Carcinosarcoma	51	IIIA2	Not received	Optimal	Paclitaxel and cisplatin x 1 cycle, then gemcitabine and paclitaxel x 3 cycles	Expired	Unexamined	Failed	-
OvCa-54	CCC-6	Clear cell	51	IIB	Not received	Optimal	Paclitaxel and cisplatin x 6 cycles	Alive	Unexamined	Success	Yes

Back to article page

ISSN: 1757-2215

Contact us

General enquiries: journalsubmissions@springernature.com